A Feasibility Study to Collect Data in Patients With Haemophilia
NCT ID: NCT00798499
Last Updated: 2009-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2008-12-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology and Immunology of Hemophilia A Inhibitors
NCT00005518
A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
NCT02049099
Bleeding Symptoms of Carriers of Hemophilia A and B
NCT01029808
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
NCT02453542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Laboratory variables
Laboratory variables
1 visit
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory variables
1 visit
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with haemophilia, all severities
* At least 18 years old.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals - AZ US
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erik Berntorp, MD, PhD, Professor
Role: PRINCIPAL_INVESTIGATOR
Malmo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Malmo, , Sweden
Research Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0960M00006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.